180 Life Sciences Corp. (ATNFW)
- Previous Close
0.0114 - Open
0.0112 - Bid --
- Ask --
- Day's Range
0.0102 - 0.0133 - 52 Week Range
0.0102 - 0.0133 - Volume
380,816 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
180lifesciences.comRecent News: ATNFW
View More
Compare To: ATNFW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATNFW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.50%
Return on Equity (ttm)
-398.58%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.55M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.45M
Company Insights: ATNFW
ATNFW does not have Company Insights